Subclinical aortic valve complex thrombus was common in patients who had undergone successful transcatheter aortic valve replacement (TAVR), but there was no significant relationship with new cerebral thromboembolism or neurologic or neurocognitive outcomes, according to a new pre-specified analysis of data from the ADAPT-TAVR trial.